Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye test tracks vision loss in dry AMD patients on approved drug

NCT ID NCT07582042

Knowledge-focused Sponsor: University of Utah Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches how vision changes over two years in 50 people aged 65-90 with geographic atrophy (a form of dry age-related macular degeneration) who are already taking the drug pegcetacoplan. Researchers will use a special vision test that maps light sensitivity near damaged areas of the retina. The goal is to see if this test can be used in regular clinic visits to track the disease better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD) in at least one eye will be included who already receive pegcetacoplan intravitreally according to the approved label as part of their routine clinical care. The study does not assign treatment prospectively; pegcetacoplan is prescribed and administered as part of routine clinical care at the discretion of the treating physician.

Ages

65 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 65-90 years. * Geographic Atrophy (GA) secondary to dry Age-related Macular Degeneration (AMD) in at least one eye with the following criteria: * GA lesion size between 1 and 15 mm² (≈ 0.4 to 6 disc areas) * GA borders must be at least 500 μm from the edge of the 30° × 25° optical coherence tomography (OCT) image frame * No confluent GA extending into peripapillary atrophy * Receiving intravitreal pegcetacoplan per label (at least one injection before screening). * Best-corrected visual acuity (BCVA) of 0.1 - 1.0 logMAR (≈ 20/20 to 20/200 Snellen) * Able to undergo mesopic FCP and required imaging. * Informed consent provided. Exclusion Criteria: * Currently or previously active exudative macular neovascularization in the study eye. * High refractive errors (\> ±5.00 Diopters \[D\] spherical equivalent) and significant astigmatism (\> 2.50 D). * Ocular comorbidities likely to confound sensitivity or imaging (e.g., diabetic retinopathy with macular edema, retinal vein occlusion (RVO), inherited retinal disease, uncontrolled glaucoma). * Media opacity precluding reliable fundus-controlled perimetry (FCP) or imaging (e.g., dense cataract, corneal opacity, vitreous hemorrhage). * Any systemic condition judged likely to compromise participation, follow-up, or data integrity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Geographic atrophy from age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Geographic atrophy from age-related macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Utah, Department of Ophthalmology, John A. Moran Eye Center

    RECRUITING

    Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.